|
Jan 4
|
Vanda Pharmaceuticals Announces Participation in the J.P. Morgan Healthcare Conference
|
|
Dec 8
|
Calculating The Fair Value Of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)
|
|
Dec 7
|
Vanda Pharmaceuticals Acquires U.S. and Canadian Rights to PONVORY® (ponesimod), a Selective S1P1R Modulator Approved for Patients with Relapsing Multiple Sclerosis
|
|
Dec 5
|
Vanda (VNDA) Rises as FDA Accepts NDA for Gastroparesis Drug
|
|
Dec 4
|
Vanda Pharmaceuticals Announces that U.S. Food and Drug Administration Accepts New Drug Application for Tradipitant for the Treatment of Gastroparesis
|
|
Nov 8
|
Vanda Pharmaceuticals Inc (VNDA) Faces Revenue Decline Amid Generic Competition in Q3 2023
|
|
Nov 8
|
Vanda Pharmaceuticals (VNDA) Reports Break-Even Earnings for Q3
|
|
Nov 8
|
Vanda Pharmaceuticals Reports Third Quarter 2023 Financial Results
|
|
Oct 20
|
Vanda Pharmaceuticals Intends to Petition the U.S. Supreme Court in its HETLIOZ® ANDA Litigation
|
|
Sep 6
|
Vanda Pharmaceuticals Announces Participation in the H.C. Wainwright Global Investment Conference
|
|
Sep 5
|
Why Shares of Vanda Pharmaceuticals Are Dropping on Tuesday
|
|
Jul 20
|
Vanda Pharmaceuticals to Announce Second Quarter 2023 Financial Results on July 27, 2023
|